Table 3. The docking results of the target compounds.
Entry | ΔG a | K i b | Entry | ΔG a | K i b |
8a | –9.53 | 0.104 | 8l | –10.52 | 0.019 |
8b | –8.53 | 0.561 | 8m | –9.65 | 0.084 |
8c | –9.00 | 0.253 | 8n | –9.20 | 0.179 |
8d | –8.95 | 0.274 | 8o | –9.56 | 0.098 |
8e | –9.66 | 0.082 | 8p | –9.10 | 0.214 |
8f | –9.14 | 0.198 | 8q | –8.59 | 0.503 |
8g | –9.32 | 0.147 | 8r | –9.76 | 0.069 |
8h | –9.37 | 0.135 | 8s | –8.59 | 0.505 |
8i | –9.61 | 0.090 | 8t | –8.31 | 0.815 |
8j | –10.28 | 0.029 | 8u | –10.27 | 0.030 |
8k | –9.42 | 0.125 | 8v | –9.45 | 0.119 |
Sorafenib | –11.03 | 0.008 | |||
Axitinib | –9.15 | 0.195 |
aBinding free energy (kcal mol–1).
bInhibition constant (μM).